New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine

Pasquale Niscola; Carla Mazzone; Matteo Molica; Paolo de Fabritiis

doi:10.2217/fon-2021-0220

New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine

Future Oncol. 2021 Jun;17(16):1973-1975. doi: 10.2217/fon-2021-0220. Epub 2021 Apr 21.

Authors

Pasquale Niscola¹, Carla Mazzone¹, Matteo Molica¹, Paolo de Fabritiis¹

Affiliation

¹ Hematology Unit, ASL Roma 2, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy.

PMID: 33878941
DOI: 10.2217/fon-2021-0220

No abstract available

Keywords: cedaruzidine; chronic myelomonocytic leukemia; managed care; myelodysplastic syndromes; oral decitabine; quality of life; therapeutic compliance.

Publication types

Editorial

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use*
Decitabine / therapeutic use*
Disease Management
Humans
Leukemia, Myelomonocytic, Chronic / drug therapy*
Leukemia, Myelomonocytic, Chronic / pathology
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / pathology

Substances

Antimetabolites, Antineoplastic
Decitabine